Flourié Françoise, Duboeuf Sébastien, Fay Murielle, Garraud Olivier
Laboratoire d'immuno-hématologie, Etablissement français du sang, Saint Priest en Jarez.
Ann Biol Clin (Paris). 2011 Jul-Aug;69(4):470-2. doi: 10.1684/abc.2011.0601.
Screening of alloantibodies is required before each transfusion. As part of our blood bank quality assurance, we have developed a quality indicator to monitor these false positive antibody results. We have studied 25.162 samples: sera were first screened by automated column agglutination technology (CAT). Positive results were found in 1.365 of the 25.162 samples. False positive results, ie positive screening test followed by a negative identification, were found in 271 (20%) cases. In the 116 patients remaining (43%) no factor could be evidenced. Interestingly, the percentage of patients with false positive antibody screening was stable month after month. In our experience, this percentage is very stable, it may be used as an indicator of quality laboratory and its unusual variation allows to suspect alterations of the reagents (hemolysis, loss of specificity, sensitivity).
每次输血前都需要筛查同种抗体。作为我们血库质量保证的一部分，我们制定了一项质量指标来监测这些假阳性抗体结果。我们研究了25162份样本：血清首先通过自动柱凝集技术（CAT）进行筛查。在25162份样本中，有1365份呈阳性结果。在271例（20%）病例中发现了假阳性结果，即筛查试验呈阳性但鉴定为阴性。在其余116例患者（43%）中，未发现任何因素。有趣的是，抗体筛查假阳性患者的比例逐月稳定。根据我们的经验，这一比例非常稳定，它可作为实验室质量的一个指标，其异常变化可能提示试剂出现改变（溶血、特异性丧失、敏感性降低）。
